Methods for Treating Fatty Liver Disease (NASH) with Resmetirom
Summary
USPTO published patent application US20260097039A1 disclosing methods of treating fatty liver disease (non-alcoholic steatohepatitis/NASH) and improving liver fibrosis using resmetirom (2-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile) or its pharmaceutical salts. Inventors: Rebecca Taub and Dominic Labriola. Application filed December 10, 2025, and published April 9, 2026. This is a publication of a patent application, not a granted patent.
What changed
USPTO published patent application US20260097039A1 covering methods of treating non-alcoholic steatohepatitis (NASH) and improving liver fibrosis using resmetirom or its pharmaceutical salts. The application discloses therapeutic uses of the compound for fatty liver diseases in human subjects.\n\nPatent applications are informational publications and do not create compliance obligations. Pharmaceutical companies developing or manufacturing resmetirom or similar thyroid hormone receptor beta agonists should monitor this application for potential future market exclusivity implications. Healthcare providers and researchers studying NASH treatments may reference this application for prior art purposes.
What to do next
- Monitor for updates
Archived snapshot
Apr 12, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
METHODS FOR TREATING A FATTY LIVER DISEASE
Application US20260097039A1 Kind: A1 Apr 09, 2026
Inventors
REBECCA TAUB, DOMINIC LABRIOLA
Abstract
The present disclosure provides a method of treating a fatty liver disease (e.g., non-alcoholic steatohepatitis (NASH)) in a human subject (e.g., an adult human subject) in need of such treatment (e.g., NASH/improving liver fibrosis) with 2-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-3, 5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile (resmetirom) or a pharmaceutically acceptable salt thereof. The present disclosure also provides a method of improving liver fibrosis in a human subject (e.g., an adult human subject) in need of such treatment (e.g., NASH/improving liver fibrosis) with 2-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-3, 5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile (resmetirom) or a pharmaceutically acceptable salt thereof.
CPC Classifications
A61K 31/53 A61P 1/16
Filing Date
2025-12-10
Application No.
19415190
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.